NASDAQ:DARE - Dare Bioscience Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.14 +0.03 (+2.70 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.14
Today's Range$1.09 - $1.16
52-Week Range$0.74 - $12.40
Volume212,057 shs
Average Volume1.22 million shs
Market Capitalization$12.68 million
P/E Ratio-0.92
Dividend YieldN/A
Beta2.78

About Dare Bioscience (NASDAQ:DARE)

Dare Bioscience logoDaré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. The company has license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company was incorporated in 2005 and is headquartered in La Jolla, California.

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DARE
CUSIPN/A
Phone858-926-7655

Debt

Debt-to-Equity RatioN/A
Current Ratio19.92
Quick Ratio19.92

Price-To-Earnings

Trailing P/E Ratio-0.92
Forward P/E Ratio-1.15
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash Flow$0.5907 per share
Price / Cash1.93
Book Value$1.38 per share
Price / Book0.83

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-11,500,000.00
Net MarginsN/A
Return on Equity-108.49%
Return on Assets-96.80%

Miscellaneous

Employees5
Outstanding Shares11,420,000

Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions

What is Dare Bioscience's stock symbol?

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How were Dare Bioscience's earnings last quarter?

Dare Bioscience (NASDAQ:DARE) announced its earnings results on Monday, April, 2nd. The biotechnology company reported ($0.49) EPS for the quarter. View Dare Bioscience's Earnings History.

When is Dare Bioscience's next earnings date?

Dare Bioscience is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Dare Bioscience.

What price target have analysts set for DARE?

1 brokerages have issued 1 year price objectives for Dare Bioscience's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Dare Bioscience's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Dare Bioscience.

Are investors shorting Dare Bioscience?

Dare Bioscience saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 566,690 shares, a decrease of 33.6% from the April 30th total of 853,637 shares. Based on an average daily volume of 1,204,770 shares, the days-to-cover ratio is presently 0.5 days. Currently, 5.6% of the company's shares are short sold.

Who are some of Dare Bioscience's key competitors?

Who are Dare Bioscience's key executives?

Dare Bioscience's management team includes the folowing people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 51)
  • Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 59)

Has Dare Bioscience been receiving favorable news coverage?

Headlines about DARE stock have trended positive on Saturday, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dare Bioscience earned a daily sentiment score of 0.28 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.24 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Dare Bioscience's major shareholders?

Dare Bioscience's stock is owned by a number of of institutional and retail investors. Top institutional investors include CVI Holdings LLC (4.13%). View Institutional Ownership Trends for Dare Bioscience.

Which major investors are buying Dare Bioscience stock?

DARE stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC. View Insider Buying and Selling for Dare Bioscience.

How do I buy shares of Dare Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dare Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.14.

How big of a company is Dare Bioscience?

Dare Bioscience has a market capitalization of $12.68 million. The biotechnology company earns $-11,500,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.

How can I contact Dare Bioscience?

Dare Bioscience's mailing address is 11119 NORTH TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]


MarketBeat Community Rating for Dare Bioscience (DARE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  304
MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe DARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dare Bioscience (NASDAQ:DARE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Dare Bioscience in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 426.32%. The high price target for DARE is $6.00 and the low price target for DARE is $6.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyN/AN/AN/A
Consensus Rating Score: 3.00N/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00N/AN/AN/A
Price Target Upside: 426.32% upsideN/AN/AN/A

Dare Bioscience (NASDAQ:DARE) Consensus Price Target History

Price Target History for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ:DARE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018Roth CapitalInitiated CoverageBuy$6.00HighView Rating Details
11/9/2016Canaccord GenuityReiterated RatingBuy$6.00N/AView Rating Details
10/19/2016Leerink SwannReiterated RatingMarket Perform$1.50N/AView Rating Details
8/30/2016BarclaysLower Price TargetOverweight$5.00 ➝ $2.00N/AView Rating Details
8/18/2016WedbushDowngradeOutperform ➝ NeutralN/AView Rating Details
8/18/2016Janney Montgomery ScottDowngradeBuy ➝ NeutralN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Dare Bioscience (NASDAQ:DARE) Earnings History and Estimates Chart

Earnings by Quarter for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ:DARE) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.99 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS

Dare Bioscience (NASDAQ DARE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018        
4/2/2018Q4 2017($0.49)ViewN/AView Earnings Details
11/13/2017Q3 2017($0.29)ViewN/AView Earnings Details
8/14/2017Q2 2017($1.42)$0.64 millionViewN/AView Earnings Details
5/12/2017Q1 2017($3.10)($2.20)$1.19 millionViewN/AView Earnings Details
11/3/2016Q3 2016($4.30)($3.60)ViewN/AView Earnings Details
8/4/2016Q216($0.48)($0.40)ViewN/AView Earnings Details
5/2/2016Q116($0.43)($0.49)ViewN/AView Earnings Details
3/10/2016Q415($0.41)($0.39)ViewListenView Earnings Details
11/16/2015Q315($0.41)($0.39)ViewListenView Earnings Details
8/6/2015Q215($0.40)($0.37)ViewN/AView Earnings Details
5/6/2015Q1 2015($4.50)($4.10)ViewN/AView Earnings Details
3/19/2015Q4 2014($0.36)($0.37)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.32)($0.28)ViewN/AView Earnings Details
8/12/2014Q2 2014($0.36)($0.34)$0.03 millionViewN/AView Earnings Details
5/27/2014Q1 2014($3.52)($3.70)$0.05 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Dare Bioscience (NASDAQ:DARE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Dare Bioscience (NASDAQ DARE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.60%
Institutional Ownership Percentage: 9.59%
Insider Trading History for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ DARE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2016David R WaltDirectorBuy2,291$2.08$4,765.28166,900View SEC Filing  
2/18/2016David R. WaltDirectorBuy8,960$2.10$18,816.00165,200View SEC Filing  
2/16/2016David R. WaltDirectorBuy8,811$2.00$17,622.00156,240View SEC Filing  
2/11/2016David R. WaltDirectorBuy8,850$2.05$18,142.50147,429View SEC Filing  
2/9/2016David R. WaltDirectorBuy9,000$2.15$19,350.00138,579View SEC Filing  
2/5/2016David R. WaltDirectorBuy8,563$2.30$19,694.90129,579View SEC Filing  
2/3/2016David R. WaltDirectorBuy8,413$2.32$19,518.16121,016View SEC Filing  
2/1/2016David R. WaltDirectorBuy5,700$2.38$13,566.00112,603View SEC Filing  
1/28/2016David R. WaltDirectorBuy9,000$2.46$22,140.00106,903View SEC Filing  
1/26/2016David R. WaltDirectorBuy8,800$2.39$21,032.0097,903View SEC Filing  
1/25/2016David R. WaltDirectorBuy4,500$2.35$10,575.0097,903View SEC Filing  
1/22/2016David R. WaltDirectorBuy9,000$2.28$20,520.0089,103View SEC Filing  
1/20/2016David R. WaltDirectorBuy8,900$2.43$21,627.0080,103View SEC Filing  
1/15/2016David R. WaltDirectorBuy8,572$2.53$21,687.1671,203View SEC Filing  
1/13/2016David R. WaltDirectorBuy8,684$2.79$24,228.3662,631View SEC Filing  
1/11/2016David R. WaltDirectorBuy8,855$2.87$25,413.8553,947View SEC Filing  
1/7/2016David R. WaltDirectorBuy8,800$2.95$25,960.0045,092View SEC Filing  
1/5/2016David R. WaltDirectorBuy8,801$3.03$26,667.0336,292View SEC Filing  
11/30/2015David R WaltDirectorBuy5,374$3.25$17,465.5017,491View SEC Filing  
11/27/2015David R. WaltDirectorBuy12,117$3.32$40,228.4412,117View SEC Filing  
4/7/2015Cvf, LlcMajor ShareholderBuy333,333$6.00$1,999,998.00View SEC Filing  
4/15/2014Alan L CraneDirectorBuy1,470,582$7.00$10,294,074.00View SEC Filing  
4/15/2014Eli & Co LillyMajor ShareholderBuy733,445$7.00$5,134,115.00View SEC Filing  
4/15/2014Lux Capital Management, LlcInsiderBuy106,224$7.00$743,568.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dare Bioscience (NASDAQ DARE) News Headlines

Source:
DateHeadline
Daré Bioscience Inc (NASDAQ:DARE): When Will It Breakeven?Daré Bioscience Inc (NASDAQ:DARE): When Will It Breakeven?
finance.yahoo.com - May 26 at 9:04 AM
Dare Bioscience (DARE) Now Covered by Analysts at Roth CapitalDare Bioscience (DARE) Now Covered by Analysts at Roth Capital
www.americanbankingnews.com - May 16 at 3:41 PM
EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San DiegoEY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego
finance.yahoo.com - May 16 at 9:31 AM
Daré Bioscience launches post-coital Ovaprene studyDaré Bioscience launches post-coital Ovaprene study
seekingalpha.com - May 15 at 4:58 PM
Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive CandidateDaré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate
finance.yahoo.com - May 15 at 9:48 AM
Juniper Pharmaceuticals (JNP) CEO Alicia Secor on Q1 2018 Results - Earnings Call TranscriptJuniper Pharmaceuticals' (JNP) CEO Alicia Secor on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:08 AM
BRIEF-Daré Bioscience Appoints John Fair To Chief Business OfficerBRIEF-Daré Bioscience Appoints John Fair To Chief Business Officer
www.reuters.com - May 8 at 9:14 AM
Daré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business OfficerDaré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business Officer
finance.yahoo.com - May 8 at 9:14 AM
Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone ...Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone ...
globenewswire.com - May 7 at 9:09 AM
BRIEF-Daré Bioscience Enters Into Agreement To Acquire Product To Address Vulvar And Vaginal Atrophy In Hormone ...BRIEF-Daré Bioscience Enters Into Agreement To Acquire Product To Address Vulvar And Vaginal Atrophy In Hormone ...
www.reuters.com - May 7 at 9:09 AM
Dare Bioscience (DARE) to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive ...Dare Bioscience (DARE) to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive ...
www.streetinsider.com - May 7 at 9:09 AM
Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer PatientsDaré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer Patients
finance.yahoo.com - May 7 at 9:09 AM
Dare Bioscience (DARE) Lifted to Hold at ValuEngineDare Bioscience (DARE) Lifted to Hold at ValuEngine
www.americanbankingnews.com - May 3 at 10:04 PM
Daré Bioscience announces funding award to further the development of Ovaprene™ from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Daré Bioscience announces funding award to further the development of Ovaprene™ from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
finance.yahoo.com - April 30 at 9:28 AM
Dare Bioscience (DARE) Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ IVR Technology PlatformDare Bioscience (DARE) Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ IVR Technology Platform
www.streetinsider.com - April 25 at 4:44 PM
Daré Bioscience in-licenses contraceptive ring from Juniper Pharma; shares up 52%Daré Bioscience in-licenses contraceptive ring from Juniper Pharma; shares up 52%
seekingalpha.com - April 25 at 4:44 PM
BRIEF-Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform To Daré BioscienceBRIEF-Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform To Daré Bioscience
www.reuters.com - April 25 at 9:21 AM
Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology PlatformDaré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
globenewswire.com - April 25 at 9:21 AM
BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology PlatformBRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
www.reuters.com - April 25 at 9:21 AM
Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology PlatformDaré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
finance.yahoo.com - April 25 at 9:21 AM
Dare Bioscience (DARE) Downgraded by ValuEngineDare Bioscience (DARE) Downgraded by ValuEngine
www.americanbankingnews.com - April 14 at 2:31 PM
Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the USBlog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US
finance.yahoo.com - April 13 at 9:40 AM
Form 3 Dare Bioscience, Inc. For: Apr 09 Filed by: Grossman Jessica D.Form 3 Dare Bioscience, Inc. For: Apr 09 Filed by: Grossman Jessica D.
www.streetinsider.com - April 12 at 10:09 AM
Jessica Grossman, M.D., Joins Daré Bioscience Board of DirectorsJessica Grossman, M.D., Joins Daré Bioscience Board of Directors
finance.yahoo.com - April 11 at 9:56 AM
Baystreet Staff -Baystreet Staff -
www.baystreet.ca - April 3 at 9:36 AM
Dare Bioscience (DARE) Reports FY17 EPS Loss of $3.47Dare Bioscience (DARE) Reports FY17 EPS Loss of $3.47
www.streetinsider.com - April 3 at 9:36 AM
BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical SildenafilBRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil
www.reuters.com - April 2 at 4:37 PM
Dare Bioscience, Inc. to Host Earnings CallDare Bioscience, Inc. to Host Earnings Call
finance.yahoo.com - April 2 at 4:37 PM
Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business UpdateDaré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update
finance.yahoo.com - April 2 at 4:37 PM
Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on ...Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on ...
globenewswire.com - March 30 at 9:24 AM
Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018
finance.yahoo.com - March 29 at 9:40 AM
PLx Pharma (PLXP) & Dare Bioscience (DARE) Financial AnalysisPLx Pharma (PLXP) & Dare Bioscience (DARE) Financial Analysis
www.americanbankingnews.com - March 15 at 5:25 AM
Dare Bioscience (DARE) Reports Exclusive Development, Option Agreement with Orbis Biosciences for Long-acting ... - StreetInsider.comDare Bioscience (DARE) Reports Exclusive Development, Option Agreement with Orbis Biosciences for Long-acting ... - StreetInsider.com
www.streetinsider.com - March 14 at 10:17 AM
Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting ... - GlobeNewswire (press release)Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting ... - GlobeNewswire (press release)
globenewswire.com - March 14 at 10:17 AM
Orbis Biosciences and Daré Bioscience Collaborate to Advance Innovation for Womens Reproductive HealthOrbis Biosciences and Daré Bioscience Collaborate to Advance Innovation for Women's Reproductive Health
www.bizjournals.com - March 12 at 11:15 AM
Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive 
finance.yahoo.com - March 12 at 11:15 AM
Reviewing Athenex (ATNX) and Dare Bioscience (DARE)Reviewing Athenex (ATNX) and Dare Bioscience (DARE)
www.americanbankingnews.com - March 10 at 3:22 PM
Dare Bioscience (DARE) Presents At LD Micro Virtual Conference 2018 - SlideshowDare Bioscience (DARE) Presents At LD Micro Virtual Conference 2018 - Slideshow
seekingalpha.com - March 8 at 5:31 PM
Daré Bioscience, Inc. To Participate in the 30th Annual ROTH ConferenceDaré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 9:30 AM
Daré Bioscience, Inc. To Participate in the LD Micro Virtual ConferenceDaré Bioscience, Inc. To Participate in the LD Micro Virtual Conference
finance.yahoo.com - February 27 at 9:21 AM
Daré Bioscience, Developing Products for Women, Analysts Target, Pipeline ReviewDaré Bioscience, Developing Products for Women, Analysts Target, Pipeline Review
finance.yahoo.com - February 26 at 9:12 AM
Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal DisorderDaré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder
finance.yahoo.com - February 23 at 9:14 AM
Mid-Afternoon Market Update: Chegg Surges After Strong Q4 Results; Dare Bioscience Shares Slide - NasdaqMid-Afternoon Market Update: Chegg Surges After Strong Q4 Results; Dare Bioscience Shares Slide - Nasdaq
www.nasdaq.com - February 15 at 8:39 AM
Dare Biosciences stock plunges to pace all decliners after stock offering - MarketWatchDare Bioscience's stock plunges to pace all decliners after stock offering - MarketWatch
www.marketwatch.com - February 15 at 8:39 AM
BRIEF-Dare Bioscience Inc To Raise About $10.25 MlnBRIEF-Dare Bioscience Inc To Raise About $10.25 Mln
www.reuters.com - February 13 at 4:21 PM
Today’s Research Reports on Trending Tickers: Dare Bioscience and MannKindToday’s Research Reports on Trending Tickers: Dare Bioscience and MannKind
finance.yahoo.com - February 13 at 9:21 AM
BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSADBRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD
www.reuters.com - February 12 at 9:11 AM
Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal DisorderDaré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder
finance.yahoo.com - February 12 at 9:10 AM
Daré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor ConferenceDaré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:12 AM
Dare Bioscience (DARE) vs. The Competition Head to Head ComparisonDare Bioscience (DARE) vs. The Competition Head to Head Comparison
www.americanbankingnews.com - January 13 at 9:36 PM

SEC Filings

Dare Bioscience (NASDAQ:DARE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dare Bioscience (NASDAQ:DARE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dare Bioscience (NASDAQ DARE) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.